Theseus Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Theseus Pharmaceuticalss Gewinne werden voraussichtlich um 6.3% pro Jahr sinken. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.2% pro Jahr.

Wichtige Informationen

-6.3%

Wachstumsrate der Gewinne

14.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.3%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	12 Feb 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Feb 01

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

Aug 18

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

May 05

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Dec 07

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Aug 11

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

Apr 22

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:THRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-66	N/A	-55	1
12/31/2025	N/A	-53	N/A	-42	1
12/31/2024	N/A	-49	N/A	-39	1
12/31/2023	N/A	-56	N/A	-48	1
9/30/2023	N/A	-57	-50	-50	N/A
6/30/2023	N/A	-58	-46	-46	N/A
3/31/2023	N/A	-55	-44	-44	N/A
12/31/2022	N/A	-51	-33	-33	N/A
9/30/2022	N/A	-46	-33	-33	N/A
6/30/2022	N/A	-38	-31	-31	N/A
3/31/2022	N/A	-33	-30	-30	N/A
12/31/2021	N/A	-27	-27	-27	N/A
9/30/2021	N/A	-22	-19	-19	N/A
6/30/2021	N/A	-16	-14	-14	N/A
3/31/2021	N/A	-13	-9	-9	N/A
12/31/2020	N/A	-12	-5	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: THRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: THRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: THRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von THRX schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: THRX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von THRX in 3 Jahren voraussichtlich hoch sein wird

Theseus Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 70% to US$6.75

Recent updates

Theseus Pharmaceuticals Files Form 15

Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from NASDAQ Composite Index

Concentra Biosciences, LLC completed the acquisition of Theseus Pharmaceuticals, Inc. (NasdaqGS:THRX).

Theseus Pharmaceuticals' Common Stock to be Cease Trading on Nasdaq at the Opening of Trading on February 14, 2024, and Intends Promptly to Cause to be Delisted from Nasdaq

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Theseus Pharmaceuticals, Inc. Announces Employment Termination of Timothy P. Clackson as Chief Executive Officer, Effective December 7, 2023

Theseus Pharmaceuticals, Inc. announced delayed 10-Q filing

Key Executive exercised options to buy US$555k worth of stock.

New minor risk - Market cap size

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

New major risk - Share price stability

Price target decreased by 70% to US$6.75

Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of The-630 in Patients with Gist

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Less than half of directors are independent

Theseus Pharmaceuticals Presents Preclinical Data Characterizing The-349, Its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium

Theseus Pharmaceuticals, Inc. Appoints Steven Stein to Board of Directors

Theseus Pharmaceuticals, Inc. Nominates The-349, A Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from Russell 2000 Growth Index

Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors

Less than half of directors are independent

Theseus Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

Theseus Pharmaceuticals, Inc. Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (Egfr) Inhibitors At the 2022 American Association for Cancer Research (Aacr) Annual Meeting

Theseus Pharmaceuticals Announces First Patient Treated with The-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors

Less than half of directors are independent

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken